Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.
Unlock the market timeline & signal feed
21 signals in the last 90 days.
The order this company entered each market — oldest to newest
AI-powered chest X-ray analysis for faster, more accurate diagnoses
16 active postings
Sign up to see the full signal feed
How Lunit Cancer Screening's international expansion compares to its competitors
Lunit Cancer ScreeningYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Lunit Cancer ScreeningYou | 2 | 0 | +800% | 20 | 65 |
(Seoul) Senior AX Engineer
View postingSeoul, Seoul, South Korea · Full-time · 3d ago
(Global) Technical Service Engineer · Japan
View postingTokyo, Tokyo, Japan · 4d ago
(Global) Director, Clinical Deployment & Growth - Lunit SCOPE
View postingFlorida, United States · 4d ago
Watch On-Demand: Measuring the Clinical Impact of AI in 3D Breast Imaging
EndedWatch On-Demand: Measuring the Clinical Impact of AI in 3D Breast Imaging
EndedWatch On-Demand: Measuring the Clinical Impact of AI in 3D Breast Imaging
EndedLunit faces a dilemma with its stock price due to derivative financial liability valuation gains. The company plans a 250 billion won rights offering to address convertible bond early redemption concerns, but the accounting issue remains unresolved.
Lunit presents 21 research findings at ECR 2026, showcasing AI solutions for mammography, chest X-ray analysis, and breast density quantification.
Lunit will present six research studies on its AI biomarker platform at AACR 2026, showcasing advancements in cancer research and treatment prediction.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Lunit Cancer Screening's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
